カンナビジオールのようなカンナビノイドは大きな治療効果を期待されているが、現在利用可能なドラッグ・デリバリー・フォーマットや現在進行中のR&Dは、原薬の吸収や患者のコンプライアンスに関して課題を抱えている。 このウェビナーでは、CBDのバイオアベイラビリティを向上させ、かつ患者に優しい高原薬負荷のフォーマットを可能にするための綿密な技術評価から得られた知見を紹介する。
スピーカー
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Explore how dsm-firmenich can help pharma raise the bar in patient-centricity and sustainability.
New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.